PLUR beat EPS expectations by 13.88%
Nov 16, 2025, 11:37 AM
0.00%
What does PLUR do
Pluri, formerly Pluristem Therapeutics Inc., is an IL-based biotechnology company focused on cell-based products for pharmaceuticals, food technology, and agriculture, with over 140 patents across 52 countries. Their research includes cell transformation technologies and therapeutic programs for various medical conditions.
Pluri (PLUR) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Pluri's actual EPS was -$0.65, beating the estimate of -$0.75 per share, resulting in a 13.88% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.